Lifecore Biomedical (LFCR) reported late Thursday its fiscal Q2 swung to a loss of $0.25 per diluted share from earnings of $0.39 per share a year earlier.
Three analysts polled by FactSet expected a loss of $0.29.
Revenue for the three months ended Nov. 24 was $32.6 million, up from $30.2 million a year ago.
Three analysts polled by FactSet expected $29.7 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。